Learning Objectives:
1. To define the role of PD-L1 in selecting patients for front line immunotherapy
2. To evaluate the potential of TMB as a biomrker for immunotherapy
3. To review the role chemo sparing regimen in treating lung cancer
Session date:
07/13/2020 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Hossein Borghaei, DO, MS